ABSTRACT
Adverse drug reactions (ADR) challenge successful anti-tuberculosis treatment (ATT). The aim of this study was to evaluate the impact of ATT-associated ADR and related factors on treatment outcomes. A prospective cohort study of persons with tuberculosis at a referral center in Rio de Janeiro, Brazil, from 2010 to 2016. ADRs, favorable (cure and treatment completion) and unfavorable (death, loss to follow up and failure) outcomes were prospectively captured. The Kaplan-Meier curve was used to estimate probability ADR-free time. A logistic regression model was performed to identify independent associations with unfavorable outcomes. 550 patients were enrolled and 35.1% were people living with HIV (PLHIV). ADR occurred in 78.6% of participants and was associated with favorable outcomes. Smokers (OR:2.32;95%CI:1.34-3.99) and illicit drug users (OR:2.02;95%CI:1.15-3.55) exhibited higher risk of unfavorable outcome. PLHIV more frequently experienced grade 3/4-ADR, specially “liver and biliary system disorders”. Lower CD4 counts were associated with hepatotoxicity (p=0.03). Male sex, low schooling, smoking and illicit-drug use are independent risk factors for unfavorable outcomes, as well alcohol abuse and previous ART in PLHIV. ADR increases the odds of favorable outcomes, although it is more severe in PLHIV and related to a higher risk of hepatotoxicity.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This work was supported by Brazilian Program of STD-AIDS and Viral Hepatitis, in partnership with the UNODC and the Clinical Research Laboratory on Mycobacteria of INI, FIOCRUZ, edital modalidade pesquisas nº 01/2013. The study was partially supported by the Intramural Research Program of the Fundac?a?o Oswaldo Cruz. B.B.A and V.C.R. are senior scientists from the Conselho Nacional de Desenvolvimento Cienti?fico e Tecnolo?gico (CNPq). M.B.A. received a scholarship from Fundac?a?o de Amparo a? Pesquisa do Estado da Bahia (FAPESB). M.A.P. received a research fellowship from the Coordenac?a?o de Aperfeic?oamento de Pessoal de Ni?vel Superior (CAPES, finance code: 001). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Not Applicable
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The study was approved by the Institutional Review Board of the National Institute of Infectious Diseases Evandro Chagas (INI) (CAAE: 86215118.5.0000.5262). Written informed consent was obtained from all participants involved in the study and all clinical investigations were conducted according to the principles expressed in the Declaration of Helsinki.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Not Applicable
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Not Applicable
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Not Applicable
Data Availability
All relevant data are within the manuscript and its Supporting Information files.
